Revenue Insights: Vertex Pharmaceuticals Incorporated and BeiGene, Ltd. Performance Compared

Biotech Giants: Vertex vs. BeiGene Revenue Growth

__timestamp	BeiGene, Ltd.	Vertex Pharmaceuticals Incorporated
Wednesday, January 1, 2014	13035000	580415000
Thursday, January 1, 2015	8816000	1032336000
Friday, January 1, 2016	1070000	1702177000
Sunday, January 1, 2017	238387000	2488652000
Monday, January 1, 2018	198220000	3047597000
Tuesday, January 1, 2019	428212000	4162821000
Wednesday, January 1, 2020	308874000	6205683000
Friday, January 1, 2021	1176283000	7574400000
Saturday, January 1, 2022	1415921000	8930700000
Sunday, January 1, 2023	2458779000	9869200000
Monday, January 1, 2024		11020100000

Unlocking the unknown

Revenue Growth: Vertex Pharmaceuticals vs. BeiGene, Ltd.

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, Vertex Pharmaceuticals Incorporated and BeiGene, Ltd. have shown remarkable trajectories. From 2014 to 2023, Vertex Pharmaceuticals has consistently outperformed, with a revenue increase of over 1,600%, reaching nearly $10 billion in 2023. This growth underscores Vertex's strong market position and innovative pipeline.

Conversely, BeiGene, Ltd. has demonstrated an impressive growth rate of over 18,000% during the same period, albeit from a smaller base. By 2023, BeiGene's revenue surged to approximately $2.5 billion, reflecting its expanding influence in the oncology sector.

This comparison highlights the contrasting scales and growth strategies of these two biotech giants, offering valuable insights into their market dynamics and future potential.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025